Allergan receives FDA approval for Ozurdex for use in certain DME patients

Article

Allergan recently announced it has received U.S. Food and Drug Administration (FDA) approval for Ozurdex (dexamethasone intravitreal implant) 0.7 mg as a new treatment option for diabetic macular edema (DME) in adult patients who have an artificial lens implant (pseudophakic) or are scheduled for cataract surgery (phakic).

Irvine, CA-Allergan recently announced it has received U.S. Food and Drug Administration (FDA) approval for Ozurdex (dexamethasone intravitreal implant) 0.7 mg as a new treatment option for diabetic macular edema (DME) in adult patients who have an artificial lens implant (pseudophakic) or are scheduled for cataract surgery (phakic). 

Ozurdex is a sustained-release, biodegradable steroid implant that demonstrated long-term efficacy without the need for monthly injections. The implant uses the Novadur solid polymer delivery system, a biodegradable implant that releases medicine over an extended period of time to suppress inflammation.

Ozurdex is already indicated for the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion and for the treatment of non-infectious uveitis affecting the posterior segment of the eye.

The latest FDA approval for Ozurdex is based on the Macular Edema: Assessment of Implantable Dexamethasone in Diabebetes (MEAD) study, which includes two multi-center, three-year, sham-controlled, masked, randomized clinical studies assessing the proportion of patients with 15 or more letters improvement in best-corrected visual acuity from baseline. The most common adverse events during the MEAD studies included cataracts and elevated intraocular pressure (IOP). An increase in mean IOP was seen with each treatment cycle, but the mean IOP generally returned to baseline between treatment cycles. 

Recent Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Pediatric optometrist Dr. Magdela Stec speaks about myopia management at EyeCon 2024
Dr. Mark Dunbar chats about his EyeCon 2024 presentation about diabetic eye care
Dr. Khanh Hoang at EyeCon 2024 receiving the Visionary in Eye Care Award
Dr Adam Wenick at EyeCon 2024
David Chin Yee, MD, at EyeCon 2024
Dr. Adam Ramsey discusses innovation for your eye care practice at EyeCon 2024
Dr. Leonard Messner at EyeCon 2024
Dr. Adam Wenick at EyeCon 2024
EyeCon 2024: Insights on transforming ocular surface disease management
© 2024 MJH Life Sciences

All rights reserved.